The first U.S. Food and Drug Administration–approved PSMA-targeted RPT for prostate cancer (PCa), 177Lu-PSMA-617 (Pluvicto; Novartis), has been shown to extend progression-free survival in men with mCRPC before and after taxane chemotherapy and to extend overall survival in posttaxane mCRPC (3). Here, FOLH1 is linked to prostate cancer.